REDWOOD CITY, Calif.,
May 27, 2015 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced that
results from four Oncotype DX® studies will be presented at the
2015 American Society of Clinical Oncology (ASCO) Annual Meeting,
which will take place May 29-June 2
at McCormick Place in Chicago. The results highlight the
following:
- Evidence regarding the impact of positive or uncertain surgical
margins on the strong association of the Oncotype DX DCIS Score™
with the likelihood of local recurrence in patients with a
pre-invasive form of breast cancer known as DCIS (ductal carcinoma
in situ).
- Report by the investigators of the large National Cancer
Institute (NCI)-sponsored Trial Assigning IndividuaLized Options
for Treatment (Rx), or TAILORx, on the baseline distribution of
Oncotype DX Recurrence Score® results in different racial and
ethnic groups of patients.
- The importance of utilizing multiple biological pathways to
predict tumor behavior in prostate cancer.
Results of the studies will be presented as follows (all times
are Central Daylight Time) and abstracts are now available at
http://abstracts.asco.org:
Saturday, May 30
- Title: "Correlation between the DCIS Score and
traditional clinicopathologic features in the
prospectively-designed Ontario
population-based validation study" (Abstract #581)
Authors: Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL,
Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA,
Bonin M, Chang MC, Robertson S, Slodkowska E, Fong CH, Anderson JM,
Jamshidian F, Cherbavaz DB, Shak S, Paszat L.
Location: S Hall A; Poster Board #70
Time: 8 – 11:30 a.m.
- Title: "Risk after local excision alone for DCIS
patients" (Abstract #1013)
Authors: Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL,
Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA,
Bonin M, Chang MC, Robertson S, Slodkowska E, Fong CH, Anderson JM,
Jamshidian F, Cherbavaz DB, Shak S, Paszat L.
Poster Discussion Session Location and Time: N Hall B1; 3 –
4:15 p.m.
Poster Location and Time: S Hall A; 8 – 11:30 a.m.; Poster Board #127
- Title: "Recurrence score and clinicopathologic
characteristics of TAILORx participants by race and ethnicity"
(Abstract #533)
Authors: Rubinstein M, Gray RJ, Sparano JA, Zujewski J,
Whelan TJ, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Keane
MM, Vallejos C, Goggins TF, Mayer IA, Brufsky A, Toppmeyer D,
Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.
Location: S Hall A; Poster Board #21
Time: 8 – 11:30 a.m.
- Title: "Evaluation of the contribution of individual
gene groups to a 17-gene prognostic prostate cancer signature"
(Abstract #5060)
Authors: Knezevic D, Ruixiao L, Burke E, Rothney M, Zhang N,
Lawrence HJ, Febbo P.
Location: S Hall A; Poster Board #54
Time: 1:15 – 4:45 p.m.
About Oncotype DX®
The Oncotype DX® portfolio of
breast, colon and prostate cancer tests applies advanced genomic
science to reveal the unique biology of a tumor in order to
optimize cancer treatment decisions. With half a million patients
tested in more than 80 countries, the Oncotype DX tests have
redefined personalized medicine by making genomics a critical part
of cancer diagnosis and treatment. To learn more
about Oncotype DX tests, visit www.OncotypeDX.com,
www.mybreastcancertreatment.org and
www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ:
GHDX) is the world's leading provider of genomic-based diagnostic
tests that address both the overtreatment and optimal treatment of
early-stage cancer, one of the greatest issues in healthcare today.
The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive
amounts of genomic data into clinically-actionable results for
treatment planning throughout the cancer patient's journey, from
diagnosis to treatment selection and monitoring. The company
is based in Redwood City, California, with
European headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits and attributes
of the company's tests. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: the risks and uncertainties
associated with the regulation of the company's tests; the results
of clinical studies; the applicability of clinical study results to
actual outcomes; the risk that the company may not obtain or
maintain sufficient levels of reimbursement, domestically or
abroad, for its existing tests and any future tests it may develop;
the risks of competition; unanticipated costs or delays in research
and development efforts; and the other risks set forth in the
company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on
Form 10-Q for the quarter ended March 31, 2015. These
forward-looking statements speak only as of the date
hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/multiple-oncotype-dx-presentations-at-the-american-society-of-clinical-oncology-annual-meeting-highlight-genomic-healths-leadership-in-personalizing-breast-prostate-cancer-care-300089040.html
SOURCE Genomic Health, Inc.